BioSpace News Archive

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant and/or allowance of a series of patents and patent applications

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company”), announced today that it will be presenting virtually this week at the 28th International Biodetection Technologies Conference as well as hosting a virtual booth at the 65th Annual CARPHA Health Research Conference.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Magenta Investments, a leading pharmaceutical and healthcare company that is part of an investment and industrial conglomerate in the United Arab Emirates (UAE), today announced a new agreement to distribute the Moderna COVID-19 Vaccine

An obese Ohio man suffering debilitating back pain began his search for relief by consulting with four different spine surgeons in his home state.

The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced the 2021 class of the Pew-Stewart Scholars Program for Cancer Research.

A U.S. clinical trial of a COVID-19 rapid test approved by an institutional review board found the Specificity of confirmed negative Covid-19 patients by RT-PCR was 100% (95% CI, 88.4%-100.0%); meaning there was 100% agreement between a negative RT-PCR and negative Clungene® serological test result.

Nineteen percent of COVID-19 patients without symptoms went on to exhibit at least one of the post-COVID conditions known as long-haul COVID 30 days or more after their initial COVID-19 diagnosis.1 This is among the findings in FAIR Health’s new white paper, the eighth of its COVID-19 studies, A Detailed Study of Patients with Long-Haul COVID: An Analysis of Private Healthcare Claims.

PulmoSIM Therapeutics (PulmoSIM), the pharmaceutical subsidiary of VeriSIM Life, Inc., is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for asset PT001 for the treatment of Pulmonary Arterial Hypertension (PAH).

Clearside Biomedical, Inc. announced positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX administered by suprachoroidal injection via Clearside’s SCS Microinjector® in six patients with neovascular age-related macular degeneration.

VBL Therapeutics provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec, for the treatment of platinum-resistant ovarian cancer.